EGFR and lung adenocarcinoma: The activation of NF-κB by the Wnt pathway was observed in a previous study of lung adenocarcinoma cells, where progesterone membrane component 1 conferred resistance to EGFR-targeted therapy and augmented the activity of the NF-κB pathway by upregulation of the Wnt pathway [46].